Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Disease analysis > Oncology

Oncology


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Market Spotlight: Basal Cell Carcinoma

    $1,318.00

    This Market Spotlight report covers the Basal Cell Carcinoma market, comprising key marketed and pipeline drugs, epidemiology, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    June 23, 2022
    Find out more
  • bladdercancer_cover

    Disease Analysis: Bladder Cancer

    Read More

    Bladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria, dysuria, increased urinary frequency, and frequent urinary tract infections.

    June 28, 2022
    Find out more
  • Market Spotlight: Benign Prostatic Hyperplasia (BPH)

    $1,318.00

    This Market Spotlight report covers the Benign Prostatic Hyperplasia (BPH) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

    April 21, 2022
    Find out more
  • Market Spotlight: Cervical Cancer

    $1,318.00

    This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    June 9, 2022
    Find out more
  • Triple-Negative Breast Cancer KOL Interview – UK

    $599.00

    A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

    October 31, 2019
    Find out more
  • Disease Analysis: Melanoma

    Read More

    Melanoma accounts for just 1% of all skin cancer cases, but is responsible for the majority of skin cancer-related deaths. Melanoma occurs when melanocytes – pigment-producing cells of the skin that are intercalated in the basal cell layer – become malignant. Although surgical excision is a potentially curative option for many melanoma patients, the disease can disseminate rapidly. Currently, only 27.3% of patients diagnosed with distant metastatic melanoma survive for five years, compared to about 99.0% of those with localized disease. Although 83% of patients present with localized disease, approximately one quarter to one third of these patients will eventually experience disease recurrence.

    June 22, 2022
    Find out more
  • Bladder Cancer KOL Interview – US

    $599.00

    A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.

    May 31, 2019
    Find out more
  • Type 1 Diabetes KOL Interview – US, Midwest

    $599.00

    This interview with a US Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market.

    January 8, 2020
    Find out more
  • Disease Analysis: Triple-Negative Breast Cancer

    Read More

    Triple-negative breast cancer (TNBC) is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.

    May 20, 2022
    Find out more
  • chronic lymphocytic leukemia

    Chronic Lymphocytic Leukemia (CLL)

    Read More

    The CLL treatment paradigm has changed significantly over the past five years, with targeted therapies such as Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors displacing chemotherapy-based treatments for most patients who have CLL.

    July 7, 2022
    Find out more
  • Disease Analysis: Renal Cell Carcinoma (RCC)

    Read More

    Sutent is set to lose ground due to both newer, more effective treatments and imminent biosimilar erosion. Previously the SOC across many treatment settings, the pivotal trials of several newer therapies, which include checkpoint inhibitors Keytruda, Opdivo, and Bavencio, and the RTK inhibitor Cabometyx, have demonstrated significant clinical benefit over Sutent in the first-line setting. Keytruda and Cabometyx have also demonstrated benefit over Sutent in subsequent-line settings.

    June 29, 2022
    Find out more
  • FOLLICULAR LYMPHOMA

    Disease Analysis: NHL: Follicular Lymphoma

    Read More

    Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL) specifically originating from centrocyte and centroblast B cells and usually beginning in the lymph nodes. The disease is among the most common forms of NHL alongside diffuse large B-cell lymphoma (DLBCL), accounting for approximately 35% of all NHLs.

    March 10, 2022
    Find out more
  • Disease Analysis: Ovarian Cancer

    Read More

    Ovarian cancer is defined as a group of tumors that originate in the ovaries. Most ovarian cancers are epithelial carcinomas which begin in the tissue surrounding the ovary. Other less common types of ovarian tumors include primary peritoneal, fallopian tube, and malignant germ cell tumors. Ovarian cancer is the fourth most common cancer among women, and is the leading cause of gynecological cancer-related death in women.

    May 19, 2022
    Find out more
  • Market Spotlight: Waldenström Macroglobulinemia (WM)

    $1,318.00

    This Market Spotlight report covers the Waldenström Macroglobulinemia (WM) market, comprising key marketed and pipeline drugs, probability of success, clinical trials, regulatory events, recent events and analyst opinion, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

    May 5, 2022
    Find out more
  • Market Spotlight: Glioblastoma (GBM)

    $1,318.00

    This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    April 14, 2022
    Find out more
Page 1 of 4
Page 1 of 41234
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top